Search Thermo Fisher Scientific
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Brivekimig is a trispecific pentavalent nanobody targeting CD252 (OX40L) TNF- alpha and albumin. It modulates immune responses by blocking inflammatory cytokines and extends therapeutic half-life through albumin binding. It is being investigated for autoimmune conditions such as ulcerative colitis and type 1 diabetes.
仅用于科研。不用于诊断过程。未经明确授权不得转售。